#Sovaldi

A review of the major findings presented at the Annual Meeting of the American Association for the Study of Liver Diseases in San Francisco

Nearly all those treated in a recent trial were cured.

The high cost of hepatitis C treatment in the U.S. is about to see a major shift to lower prices of the major leading hepatitis C treatments

This Ukrainian woman didn’t let outdated hepatitis C treatment or limited access to them, prevent her from getting necessary medical care.

Genotype 3 of hepatitis C virus is typically difficult to treat.

A photographer helps his mom get cured of hep C after reading Hep magazine.

More than 125,000 veterans will have received lifesaving cures by October 2018.

With many hepatitis C treatments on the market today, patients may ask which hepatitis C treatment is right for me? What’s the difference?

The annual scientific meeting on liver health revealed exciting new findings concerning the battle against the hep C epidemic.

In a recent study of more than 600 HIV-positive adults, 93 percent were cured of hep C.

Sovaldi (sofosbuvir) plus the new hep C drug ravidasvir cured 97 percent of those with a range of genotypes in a recent study.

Among those without cirrhosis, treating for an additional four weeks is unnecessary.

A recent study of Dutch clinicians found that they generally did a good job of preventing drug-drug interactions.

Ending the epidemic is going to require addressing the fact that certain individuals are at high risk of reinfection after a cure.